The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

Objectives We aimed to investigate which elementary lesions, identified through conventional brain MRI, correlated with the attribution of neuropsychiatric (NP) manifestations of SLE as determined by ...

Specifically, among primary HER2–0 tumors, about one-third (31.7%) converted to HER2-low at recurrence (and a small subset ~3% converted to HER2-positive) . Anderson et al. examined 171 paired primary ...

Phase 1 1 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors.

DESTINY-Breast09 is a multicenter open-label three-arm study of 1,157 patients with HER2-positive advanced or metastatic breast cancer. They are disease free for >6 months from their last ...

In the multicenter, open-label DESTINY-Breast09 study, patients with HER2-positive metastatic or advanced breast cancer were randomly assigned 1:1:1 to receive Enhertu at 5.4 milligram per kilogram ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A ...

The brain is like an ecosystem—thousands of different types of cells connect to form one big, interdependent web.And just as biologists document species of plants and animals, neuroscientists ...

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) is a classical oncogene that was first shown to be actionable in breast cancer three decades ago. Its overexpression was first ...

The study included 1,157 patients with HER2-positive locally advanced or metastatic breast cancer who had not received treatment with chemotherapy or HER2-targeted therapy. The patients were randomly ...